治疗前高全身免疫炎症指数值可预测胰腺癌最终化疗后的不良预后

IF 1.9 4区 医学 Q3 ONCOLOGY
Clinical Medicine Insights-Oncology Pub Date : 2024-11-07 eCollection Date: 2024-01-01 DOI:10.1177/11795549241298552
Erkan Topkan, Ahmet Kucuk, Duriye Ozturk, Emine Elif Ozkan, Nilüfer Kılıç Durankuş, Şükran Şenyürek, Ugur Selek, Berrin Pehlivan
{"title":"治疗前高全身免疫炎症指数值可预测胰腺癌最终化疗后的不良预后","authors":"Erkan Topkan, Ahmet Kucuk, Duriye Ozturk, Emine Elif Ozkan, Nilüfer Kılıç Durankuş, Şükran Şenyürek, Ugur Selek, Berrin Pehlivan","doi":"10.1177/11795549241298552","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The systemic immune-inflammation index (SII) is an effective tool for predicting the prognosis of patients with cancer. However, its value in patients with locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) undergoing definitive chemoradiotherapy has yet to be addressed. Therefore, we aimed to retrospectively investigate the prognostic significance of the pretreatment SII on the survival outcomes of patients with unresectable LA-PDAC treated with concurrent chemoradiotherapy (C-CRT).</p><p><strong>Methods: </strong>The study included 163 patients with LA-PDAC who had received C-CRT. Using receiver operating characteristic (ROC) curve analysis, the utility of a pre-C-CRT cutoff that could stratify survival results was investigated. The primary and secondary endpoints were the correlations between SII levels and overall survival (OS) and progression-free survival (PFS).</p><p><strong>Results: </strong>At a median follow-up period of 15 months (range: 3.2-94.5), the median OS and PFS rates for the entire group were 15.7 months (95% confidence interval [CI]: 13.4-17.9), and 7.8 months (95% CI: 6.1-9.4), respectively. We divided the patients into 2 SII cohorts based on the ROC curve analysis (area under the curve [AUC]: 71.9%; sensitivity: 68.9%; specificity: 66.7%): SII < 538 (N = 70) and SII ⩾ 538 (N = 93). Comparative survival analysis showed significantly inferior median OS (13.0 vs 25.4 months; <i>P</i> < .001) and PFS (7.0 vs 15.2 months; <i>P</i> = .003) in patients with SII ⩾ 538 compared with those with SII < 538 before treatment. In multivariate analyses, the Eastern Cooperative Oncology Group (ECOG) performance of 2, N1-2 lymph node, CA 19-9 > 90 U/mL, and SII ⩾ 538 status emerged as independent prognosticators of inferior OS and PFS.</p><p><strong>Conclusions: </strong>Present results indicate that patients with unresectable LA-PDAC who underwent C-CRT and had a pretreatment SII ⩾ 538 had significantly worse OS and PFS outcomes compared with those with lower SII values.</p>","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"18 ","pages":"11795549241298552"},"PeriodicalIF":1.9000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544671/pdf/","citationCount":"0","resultStr":"{\"title\":\"High Systemic Immune-Inflammation Index Values Before Treatment Predict Poor Pancreatic Cancer Outcomes After Definitive Chemoradiotherapy.\",\"authors\":\"Erkan Topkan, Ahmet Kucuk, Duriye Ozturk, Emine Elif Ozkan, Nilüfer Kılıç Durankuş, Şükran Şenyürek, Ugur Selek, Berrin Pehlivan\",\"doi\":\"10.1177/11795549241298552\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The systemic immune-inflammation index (SII) is an effective tool for predicting the prognosis of patients with cancer. However, its value in patients with locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) undergoing definitive chemoradiotherapy has yet to be addressed. Therefore, we aimed to retrospectively investigate the prognostic significance of the pretreatment SII on the survival outcomes of patients with unresectable LA-PDAC treated with concurrent chemoradiotherapy (C-CRT).</p><p><strong>Methods: </strong>The study included 163 patients with LA-PDAC who had received C-CRT. Using receiver operating characteristic (ROC) curve analysis, the utility of a pre-C-CRT cutoff that could stratify survival results was investigated. The primary and secondary endpoints were the correlations between SII levels and overall survival (OS) and progression-free survival (PFS).</p><p><strong>Results: </strong>At a median follow-up period of 15 months (range: 3.2-94.5), the median OS and PFS rates for the entire group were 15.7 months (95% confidence interval [CI]: 13.4-17.9), and 7.8 months (95% CI: 6.1-9.4), respectively. We divided the patients into 2 SII cohorts based on the ROC curve analysis (area under the curve [AUC]: 71.9%; sensitivity: 68.9%; specificity: 66.7%): SII < 538 (N = 70) and SII ⩾ 538 (N = 93). Comparative survival analysis showed significantly inferior median OS (13.0 vs 25.4 months; <i>P</i> < .001) and PFS (7.0 vs 15.2 months; <i>P</i> = .003) in patients with SII ⩾ 538 compared with those with SII < 538 before treatment. In multivariate analyses, the Eastern Cooperative Oncology Group (ECOG) performance of 2, N1-2 lymph node, CA 19-9 > 90 U/mL, and SII ⩾ 538 status emerged as independent prognosticators of inferior OS and PFS.</p><p><strong>Conclusions: </strong>Present results indicate that patients with unresectable LA-PDAC who underwent C-CRT and had a pretreatment SII ⩾ 538 had significantly worse OS and PFS outcomes compared with those with lower SII values.</p>\",\"PeriodicalId\":48591,\"journal\":{\"name\":\"Clinical Medicine Insights-Oncology\",\"volume\":\"18 \",\"pages\":\"11795549241298552\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544671/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine Insights-Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/11795549241298552\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11795549241298552","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:全身免疫炎症指数(SII)是预测癌症患者预后的有效工具:全身免疫炎症指数(SII)是预测癌症患者预后的有效工具。然而,它在接受明确化放疗的局部晚期胰腺导管腺癌(LA-PDAC)患者中的价值尚未得到研究。因此,我们旨在回顾性研究治疗前 SII 对接受同期化放疗(C-CRT)的不可切除 LA-PDAC 患者生存预后的意义:研究纳入了163例接受C-CRT治疗的LA-PDAC患者。研究采用接收器操作特征曲线(ROC)分析法,探讨了CRT前分界线对生存结果分层的作用。主要和次要终点是SII水平与总生存期(OS)和无进展生存期(PFS)之间的相关性:中位随访期为 15 个月(范围:3.2-94.5),全组患者的中位 OS 和 PFS 分别为 15.7 个月(95% 置信区间 [CI]:13.4-17.9)和 7.8 个月(95% 置信区间 [CI]:6.1-9.4)。根据 ROC 曲线分析(曲线下面积 [AUC]:71.9%;灵敏度:68.9%;特异度:66.7%),我们将患者分为两个 SII 组群:与SⅡ 90 U/mL的患者相比,SⅡ ⩾ 538的患者的SⅡ P P = .003),SⅡ ⩾ 538状态成为OS和PFS较差的独立预后指标:结论:目前的研究结果表明,与SII值较低的患者相比,接受C-CRT治疗且治疗前SII ⩾ 538的不可切除LA-PDAC患者的OS和PFS预后明显较差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
High Systemic Immune-Inflammation Index Values Before Treatment Predict Poor Pancreatic Cancer Outcomes After Definitive Chemoradiotherapy.

Background: The systemic immune-inflammation index (SII) is an effective tool for predicting the prognosis of patients with cancer. However, its value in patients with locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) undergoing definitive chemoradiotherapy has yet to be addressed. Therefore, we aimed to retrospectively investigate the prognostic significance of the pretreatment SII on the survival outcomes of patients with unresectable LA-PDAC treated with concurrent chemoradiotherapy (C-CRT).

Methods: The study included 163 patients with LA-PDAC who had received C-CRT. Using receiver operating characteristic (ROC) curve analysis, the utility of a pre-C-CRT cutoff that could stratify survival results was investigated. The primary and secondary endpoints were the correlations between SII levels and overall survival (OS) and progression-free survival (PFS).

Results: At a median follow-up period of 15 months (range: 3.2-94.5), the median OS and PFS rates for the entire group were 15.7 months (95% confidence interval [CI]: 13.4-17.9), and 7.8 months (95% CI: 6.1-9.4), respectively. We divided the patients into 2 SII cohorts based on the ROC curve analysis (area under the curve [AUC]: 71.9%; sensitivity: 68.9%; specificity: 66.7%): SII < 538 (N = 70) and SII ⩾ 538 (N = 93). Comparative survival analysis showed significantly inferior median OS (13.0 vs 25.4 months; P < .001) and PFS (7.0 vs 15.2 months; P = .003) in patients with SII ⩾ 538 compared with those with SII < 538 before treatment. In multivariate analyses, the Eastern Cooperative Oncology Group (ECOG) performance of 2, N1-2 lymph node, CA 19-9 > 90 U/mL, and SII ⩾ 538 status emerged as independent prognosticators of inferior OS and PFS.

Conclusions: Present results indicate that patients with unresectable LA-PDAC who underwent C-CRT and had a pretreatment SII ⩾ 538 had significantly worse OS and PFS outcomes compared with those with lower SII values.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.40
自引率
4.50%
发文量
57
审稿时长
8 weeks
期刊介绍: Clinical Medicine Insights: Oncology is an international, peer-reviewed, open access journal that focuses on all aspects of cancer research and treatment, in addition to related genetic, pathophysiological and epidemiological topics. Of particular but not exclusive importance are molecular biology, clinical interventions, controlled trials, therapeutics, pharmacology and drug delivery, and techniques of cancer surgery. The journal welcomes unsolicited article proposals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信